European Medicines Agency approves first-line cabozantinib for advanced kidney cancer
Cabozantinib (Cabometyx) has been granted approval by the Committee for Medicinal [...]
Cabozantinib (Cabometyx) has been granted approval by the Committee for Medicinal [...]
The following is a Practice Update interview with Dr Hans Hammers, Associate [...]
In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]
Results from a phase 1 clinical trial looking at CB-839, [...]
Data from the phase 3 METEOR trial published in the Journal [...]
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in people [...]
There are now a number of licensed drug options available [...]
Cabozantinib (Cabometyx) has been granted approval by the US Food [...]
The following video from Practise Update is an interview with [...]
This article, published in UroToday this week, is a nice summary [...]